Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06329661 · ClinicalTrials.gov registry record · Phase 4
A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine
A Phase 4 study, sponsored by Novaliq.
- Completed
- Registry status
- Phase 4
- Development phase
- 204
- Enrollment target
NCT06329661: Completed Phase 4 study, sponsored by Novaliq.
NCT06329661 is a Phase 4 study that has completed, run by Novaliq. The registered enrollment target is 204 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06329661, a Phase 4 study, has completed, sponsored by Novaliq.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 204 participants
- Enrollment target
Study Summary
The objective of this trial is to evaluate the effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell health in comparison to a hypotonic saline solution in subjects with Dry Eye Disease (DED)
Primary Outcome
Change from baseline at 12 months in ECD measured as count/mm2 using specular microscopy in the study eye
Interventions
- DRUG Cyclosporine ophthalmic solution, 0.1%
- DRUG Saline solution, 0.6%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2025-07-30 |
| Phase | Phase 4 |
What the finished NCT06329661 record still lists
NCT06329661 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 2 interventions - of which Cyclosporine ophthalmic solution, 0.1% is the first listed.
NCT06329661 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06329661 about?
NCT06329661 is a clinical study titled "A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine". The objective of this trial is to evaluate the effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell health in comparison to a hypotonic saline solution in subjects with Dry Eye Disease (DED)
What is the current status of trial NCT06329661?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 204 participants. The study started on 2024-04-22. Estimated completion is 2025-07-30.
What interventions are being tested in trial NCT06329661?
The interventions under investigation include: Cyclosporine ophthalmic solution, 0.1% (DRUG), Saline solution, 0.6% (DRUG).
Who is sponsoring clinical trial NCT06329661?
This trial is sponsored by Novaliq, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06329661's enrollment target sits among peer trials
204 402nd of 2000 higher than 1,598 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI